MCID: VPM001
MIFTS: 51

Vipoma

Categories: Rare diseases, Gastrointestinal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Vipoma

MalaCards integrated aliases for Vipoma:

Name: Vipoma 12 76 53 59 55 44 15 73
Pancreatic Cholera 59 73
Pancreatic Vipoma 53 73
Malignant Vasoactive Intestinal Peptide-Secreting Tumor 12
Watery Diarrhea-Hypokalemia-Achlorhydria Syndrome 59
Vasoactive Intestinal Peptide-Secreting Tumor 12
Vasoactive Intestinal Peptide-Producing Tumor 53
Vasoactive Intestinal Peptide Tumor 53
Diarrheogenic Islet Cell Tumor 59
Verner-Morrison Syndrome 59
Vip- Secreting Tumor 12
Vip-Secreting Tumor 59
Vipoma, Malignant 12
Malignant Vipoma 73
Wdha Syndrome 59

Characteristics:

Orphanet epidemiological data:

59
vipoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Vipoma

NIH Rare Diseases : 53 VIPoma is a rare cancer that develops within the pancreas. This tumor causes pancreatic cells to produce high levels of a hormone called vasoactive intestinal peptide (VIP). The signs and symptoms of a VIPoma include abdominal pain, flushing or redness of the face, nausea, watery diarrhea, weight loss, dehydration, and low blood potassium (hypokalemia). VIPomas are usually diagnosed in adults around age 50. The cause of VIPoma is unknown. Treatment may include intravenous (IV) fluids to correct dehydration, medications such as octreotide to help control diarrhea, and surgery to remove the tumor.

MalaCards based summary : Vipoma, also known as pancreatic cholera, is related to wdha syndrome and pancreatic cholera, and has symptoms including diarrhea An important gene associated with Vipoma is VIP (Vasoactive Intestinal Peptide), and among its related pathways/superpathways is Gastric acid production. The drugs Oxaliplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and thyroid, and related phenotypes are neoplasm of the pancreas and hypokalemia

Wikipedia : 76 A VIPoma (also known as Verner–Morrison syndrome, after the physicians who first described it) is a rare... more...

Related Diseases for Vipoma

Diseases related to Vipoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 wdha syndrome 32.5 SST VIP
2 pancreatic cholera 30.2 GAST SCT SST VIP
3 pancreatitis 29.7 SCT SST
4 diarrhea 29.6 GAST SST
5 paraganglioma 29.5 CHGA SST
6 somatostatinoma 29.2 CHGA SST VIP
7 glucagonoma 28.7 CHGA SCT SST VIP
8 carcinoid syndrome 28.5 CHGA NTS SST
9 multiple endocrine neoplasia, type i 27.6 CHGA GAST SCT SST VIP
10 neuroendocrine tumor 27.5 CHGA GAST NTS SST
11 pancreatic vasoactive intestinal peptide producing tumor 11.3
12 pancreatic neuroendocrine tumor 10.9
13 secretory diarrhea 10.4 SST VIP
14 cryptosporidiosis 10.3 SST VIP
15 pancreatic gastrinoma 10.3 SCT SST
16 pylorospasm 10.3 GAST SST
17 postcholecystectomy syndrome 10.3 GAST SST
18 angiodysplasia 10.2 SCT SST
19 hyperprolactinemia 10.2 SST VIP
20 retinitis pigmentosa 40 10.2 GAST SST
21 pernicious anemia 10.2 GAST SST
22 steatorrhea 10.2 SCT SST
23 pancreas disease 10.2 SCT SST
24 adenoma of the pancreas 10.2 CHGA SST
25 gastrointestinal neuroendocrine tumor 10.2 CHGA SST
26 pituitary carcinoma 10.1 CHGA SST
27 stomach disease 10.1 GAST SST
28 diffuse pulmonary fibrosis 10.1 CHGA VIP
29 diphyllobothriasis 10.1 GAST SCT
30 carcinoid tumors, intestinal 10.1 CHGA SST
31 pertussis 10.1 SST VIP
32 ganglioneuroma 10.1 CHGA VIP
33 autoimmune atrophic gastritis 10.1 CHGA GAST
34 goblet cell carcinoid 10.1 CHGA GAST
35 peptic ulcer disease 10.1 GAST SCT
36 phaeochromocytoma 10.1 CHGA SST
37 hepatitis 10.0
38 non-functioning pancreatic endocrine tumor 10.0 CHGA GAST
39 irritable bowel syndrome 10.0 CHGA VIP
40 acute pancreatitis 10.0 SCT SST
41 cell type benign neoplasm 10.0 CHGA SST
42 merkel cell carcinoma 9.9 CHGA SST
43 type i 9.9
44 multiple endocrine neoplasia 9.9
45 autonomic nervous system neoplasm 9.8 NTS VIP
46 short bowel syndrome 9.8 NTS SST
47 gastritis 9.8 CHGA GAST
48 ventricular fibrillation, paroxysmal familial, 1 9.7
49 ulcerative colitis 9.7
50 small cell carcinoma 9.7

Graphical network of the top 20 diseases related to Vipoma:



Diseases related to Vipoma

Symptoms & Phenotypes for Vipoma

Human phenotypes related to Vipoma:

59 32 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the pancreas 59 32 hallmark (90%) Very frequent (99-80%) HP:0002894
2 hypokalemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002900
3 secretory diarrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0005208
4 diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0000819
5 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
6 normochromic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001895
7 dehydration 59 32 frequent (33%) Frequent (79-30%) HP:0001944
8 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
9 malabsorption 59 32 frequent (33%) Frequent (79-30%) HP:0002024
10 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
11 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
12 episodic abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002574
13 hypercalcemia 59 32 frequent (33%) Frequent (79-30%) HP:0003072
14 generalized muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0003324
15 muscle cramps 59 32 frequent (33%) Frequent (79-30%) HP:0003394
16 poor appetite 59 32 frequent (33%) Frequent (79-30%) HP:0004396
17 erythema 59 32 frequent (33%) Frequent (79-30%) HP:0010783
18 chronic fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012432
19 intermittent jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0001046
20 intrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001406
21 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
22 extrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012334
23 abnormal gastrointestinal motility 59 32 occasional (7.5%) Occasional (29-5%) HP:0030895
24 increased circulating gonadotropin level 59 32 very rare (1%) Very rare (<4-1%) HP:0000837
25 growth hormone excess 59 32 very rare (1%) Very rare (<4-1%) HP:0000845
26 prolactin excess 59 32 very rare (1%) Very rare (<4-1%) HP:0000870
27 subcutaneous lipoma 59 32 very rare (1%) Very rare (<4-1%) HP:0001031
28 respiratory insufficiency due to muscle weakness 59 32 very rare (1%) Very rare (<4-1%) HP:0002747
29 pituitary adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002893
30 neoplasm of the liver 59 32 very rare (1%) Very rare (<4-1%) HP:0002896
31 parathyroid adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002897
32 ganglioneuroma 59 32 very rare (1%) Very rare (<4-1%) HP:0003005
33 elevated calcitonin 59 32 very rare (1%) Very rare (<4-1%) HP:0003528
34 benign gastrointestinal tract tumors 59 32 very rare (1%) Very rare (<4-1%) HP:0006719
35 follicular thyroid carcinoma 59 32 very rare (1%) Very rare (<4-1%) HP:0006731
36 primary hyperparathyroidism 59 32 very rare (1%) Very rare (<4-1%) HP:0008200
37 adrenocortical adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0008256
38 abnormality of the abdomen 59 Occasional (29-5%)
39 abnormality of the thyroid gland 59 Very rare (<4-1%)
40 hypercortisolism 59 Very rare (<4-1%)
41 hematochezia 59 Excluded (0%)
42 increased circulating cortisol level 32 very rare (1%) HP:0003118

UMLS symptoms related to Vipoma:


diarrhea

Drugs & Therapeutics for Vipoma

Drugs for Vipoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1 59763-91-6
9 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
10 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
11 Immunosuppressive Agents Phase 2, Phase 3
12 Liver Extracts Phase 3,Phase 2,Phase 1
13 Antimetabolites Phase 2, Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
15 Analgesics Phase 3
16 Central Nervous System Depressants Phase 3
17 Adjuvants, Anesthesia Phase 3
18 Narcotics Phase 3
19 Analgesics, Opioid Phase 3
20 Anesthetics Phase 3
21 Anesthetics, General Phase 3
22 Anesthetics, Intravenous Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
28
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
29
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
30
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
31
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
32
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
33
Melphalan Approved Phase 2 148-82-3 4053 460612
34
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
35
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
36
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
37
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
38
Everolimus Approved Phase 2 159351-69-6 6442177
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
40
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
41
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
42
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
43 Epothilone B Phase 2
44 pancreatin Phase 2,Phase 1
45 Epothilones Phase 2
46 Alkylating Agents Phase 2,Phase 1
47 topoisomerase I inhibitors Phase 2
48 Retinol palmitate Phase 2
49 Micronutrients Phase 2
50 Gastrointestinal Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
4 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
5 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
6 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
7 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
8 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
9 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
10 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
11 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
12 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
13 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
14 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
15 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
16 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
17 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
18 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
19 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
20 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
21 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
22 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
23 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Enrolling by invitation NCT02102893
24 DOTATOC PET/CT for Imaging NET Patients Not yet recruiting NCT03583528

Search NIH Clinical Center for Vipoma

Cochrane evidence based reviews: vipoma

Genetic Tests for Vipoma

Anatomical Context for Vipoma

MalaCards organs/tissues related to Vipoma:

41
Pancreas, Liver, Thyroid, Bone, Endothelial, Pituitary, Lung

Publications for Vipoma

Articles related to Vipoma:

(show top 50) (show all 134)
# Title Authors Year
1
Paediatric VIPoma: A Jamboree of Electrolytes. ( 29744252 )
2018
2
ViPoma ( 29939520 )
2018
3
Percutaneous Irreversible Electroporation for Pancreatic VIPoma: A Case Report. ( 27977628 )
2017
4
Ventricular fibrillation resulting from electrolyte imbalance reveals vipoma in MEN1 syndrome. ( 27071757 )
2016
5
Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization? ( 27583030 )
2016
6
When Symptomatic Treatment Becomes Antitumor Treatment for Vipoma: Opportunity for Frail Elderly Adults. ( 26889855 )
2016
7
Metastatic VIPoma presenting as an ovarian mass. ( 26657531 )
2015
8
VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation. ( 26564120 )
2015
9
Pancreatic VIPoma visualized by 68Ga DOTA-NOC PET-CT. ( 26235641 )
2015
10
Sunitinib Achieved Fast and Sustained Control of VIPoma Symptoms. ( 25305306 )
2014
11
Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male. ( 24785507 )
2014
12
Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. ( 25349667 )
2014
13
Extra-pancreatic vipoma. ( 25184777 )
2014
14
Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). ( 23407483 )
2013
15
VIPoma in a 37-year-old man. ( 23993192 )
2013
16
A rare cause of diarrhea: pancreatic VIPoma. ( 24008482 )
2013
17
Ischemic stroke as a presenting feature of VIPoma due to MEN 1 syndrome. ( 24251163 )
2013
18
Education and imaging. Hepatobiliary and pancreatic: pancreatic VIPomas associated with multiple endocrine neoplasia type I. ( 22353352 )
2012
19
VIPoma that arose from the rectum in a 65-year-old male patient. ( 22350188 )
2012
20
MSH2 and CXCR4 involvement in malignant VIPoma. ( 23231927 )
2012
21
Diagnosis and treatment of VIPoma: a case report and literature review in China. ( 22695090 )
2012
22
VIPoma Crisis: Immediate and life saving reduction of massive stool volumes on starting treatment with octreotide. ( 21509215 )
2011
23
Benign pancreatic vipoma. ( 21526882 )
2011
24
VIPoma syndrome: challenges in management. ( 20730389 )
2010
25
Is radiofrequency ablation justified for liver metastatic VIPoma patient undergoing Whipple procedure? ( 20819560 )
2010
26
Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma. ( 20351979 )
2010
27
Hypokalemic rhabdomyolysis due to watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome caused by vipoma. ( 19488018 )
2009
28
Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. ( 19387771 )
2009
29
VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. ( 19184565 )
2009
30
Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. ( 18662399 )
2008
31
[Diagnostic procedures and more particularly, place of scintigraphy in neuroendocrine tumors, example of vipoma in MEN 1]. ( 17292846 )
2007
32
Diagnosis and treatment of VIPoma in a female patient. ( 16357627 )
2006
33
Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. ( 16354964 )
2006
34
VIPomas: an update in diagnosis and management in a series of 11 patients. ( 16001675 )
2005
35
Calcitonin-secreting VIPoma. ( 16416161 )
2005
36
Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. ( 15657529 )
2004
37
VIPoma: a rare cause of a pancreatic mass. ( 15162993 )
2004
38
[Jejunal vipoma]. ( 15646540 )
2004
39
VIPoma. ( 15590967 )
2004
40
Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. ( 14707737 )
2004
41
Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report. ( 12482130 )
2002
42
Vipoma: effective treatment with octreotide in the oldest old. ( 11347804 )
2001
43
Dynamic gadolinium-enhanced MR imaging of pancreatic VIPoma in a patient with Verner-Morrison syndrome. ( 11702127 )
2001
44
Vasoactive Intestinal Peptide Tumor (VIPoma) ( 25905195 )
2000
45
Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil. ( 10638600 )
2000
46
VIPoma of pancreas in a child. ( 11059195 )
2000
47
Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. ( 10389687 )
1999
48
Metastatic pancreatic VIPoma: deteriorating clinical course and successful treatment by liver transplantation. ( 9577908 )
1998
49
Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. ( 9744346 )
1998
50
The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma. ( 9780538 )
1998

Variations for Vipoma

Expression for Vipoma

Search GEO for disease gene expression data for Vipoma.

Pathways for Vipoma

Pathways related to Vipoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.64 GAST SCT VIP

GO Terms for Vipoma

Cellular components related to Vipoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 CHGA GAST SCT SST
2 extracellular region GO:0005576 9.1 CHGA GAST NTS SCT SST VIP
3 transport vesicle GO:0030133 8.96 CHGA NTS

Biological processes related to Vipoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.35 GAST NTS SCT SST VIP
2 regulation of signaling receptor activity GO:0010469 9.02 GAST NTS SCT SST VIP

Molecular functions related to Vipoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 NTS VIP
2 hormone activity GO:0005179 8.92 GAST SCT SST VIP

Sources for Vipoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....